The effect of intravenous dexamethasone in supraclavicular brachial plexus block at Halibet National Referral Hospital, Eritrea 2024–2025: A randomized clinical trial Authors: Michael Beraki Mengistu, Senay Amare Habtu, Abel Mussie Elias, Sabrina Hashim Idris, Kisanet Huruy Abraha, Robert Jeenchen Chen, Robert Jeenchen Chen, Robert Jeenchen Chen, Robert Jeenchen Chen, Robert Chen, Robert Jeenchen Chen, Robert Jeenchen Chen Published: 2026 ABSTRACT BackgroundPostoperative pain has significant impact on recovery and healthcare costs. While effective regional anesthesia provides both anesthesia and analgesia, its effects are often of limited duration. Previous studies indicate that intravenous dexamethasone may enhance and prolong analgesia when used with regional blocks, yet reports on its duration to supraclavicular brachial plexus block (SCBPB) for upper limb surgeries are limited. We hypothesized that intravenous dexamethasone would extend postoperative analgesia following SCBPB.MethodA randomized clinical trial was conducted at Halibet National Referral Hospital in Eritrea, involving 60 patients undergoing upper limb surgery who received SCBPB with 20 ml of 0.5% bupivacaine. Concurrently, the control group received 2 ml of normal saline, while the experimental group received 2 ml (8 mg) of intravenous dexamethasone. Pain scores, time to first rescue analgesia, and analgesic consumption were recorded. Data were analyzed using SPSS v26.ResultsThe mean duration of analgesia was significantly longer in the dexamethasone group (17.36 ± 3.75 hours) compared to the control group (7.57 ± 1.04 hours, p < 0.001). The dexamethasone group had faster onset of sensory and motor block and lower analgesic consumption.ConclusionsIn summary, intravenous dexamethasone significantly prolonged postoperative analgesia, accelerated block onset, and reduced analgesic consumption without adverse events. These findings support its use as a practical adjunct to bupivacaine in supraclavicular brachial plexus block, with potential to improve postoperative pain management in low‑resource settings.Clinical trial registrationThis trial was registered in the Pan African Clinical Trial Registry (PACTR202509579633417). Participant recruitment occurred between September 23, 2024 and January 17, 2025, with follow‑up completed by January 18, 2025. The authors confirm that all ongoing and related trials for this intervention are registered. Introduction Pain is not merely a sensory modality but a multidimensional experience. The International Association for the Study of Pain (IASP) defines it as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage” [1]. This definition highlights the interplay between subjective perception, emotional response, and physiological mechanisms. Pain response vary widely among individuals and even within the same person over times, influenced by factors such as age, gender and psychological state. In hospital settings, both acute and chronic pain are common, making postoperative pain management essential for all patients [1]. Despite advances in postoperative pain (POP) management, significant gaps remain. Acute POP is often undertreated, particularly following general surgical procedures. Unrelieved pain can negatively affect physical and psychological well-being, delay recovery, and increase healthcare costs. Immediate consequences of severe pain include reduced mobility, sleep disturbances, increased reliance on analgesics, and impaired immune function, which may heighten susceptibility to infection [2]. Poorly managed pain can also trigger pathophysiological changes in the peripheral and central nervous systems, potentially leading to chronic pain. In such cases, central sensitization may result in exaggerated pain responses to stimuli that would otherwise be tolerable. [3]. Regional anesthesia offers excellent analgesia and is widely accepted for POP relief [4]. For upper limb surgeries, brachial plexus block (BPB) is used either as an adjunct to general anesthesia or as a sole anesthetic technique. However, the duration of analgesia is limited by the pharmacokinetics of local anesthetics (LAs). Prolongation can be achieved through indwelling perineural catheters or the addition of adjuvant drugs. While catheter techniques provide extended analgesia, they are limited by technical challenges such as placement accuracy, risk of infection, and removal difficulties [5,6]. Recent advancements in peripheral nerve block (PNB) techniques and the use of adjuvants have significantly improved analgesic outcomes. Adjuvants—agents administered alongside LAs—enhance block quality, extend analgesia duration, and improve patient recovery [7]. A comprehensive understanding of the mechanisms of action, clinical effects, and safety profiles of PNB and the use of additional adjuvants is essential. Brachial plexus blocks can be performed via interscalene, supraclavicular, infraclavicular, or axillary approaches. Among these, the supraclavicular route is preferred for procedures below the shoulder due to its consistency and ease of access. However, complications such as pneumothorax, hemothorax, Horner’s syndrome, and phrenic nerve block may occur. Ultrasound-guided supraclavicular blocks improve safety by allowing real-time visualization of anatomical structures and needle placement. Although LAs alone provide good intraoperative conditions, their effects wear off within hours, exposing patients to moderate to severe postoperative pain [8]. To address this, various adjuvants—including morphine, tramadol, fentanyl, clonidine, dexmedetomidine, and midazolam—have been used. [9]. Recently, corticosteroids such as dexamethasone have gained attention for their analgesic and antiemetic properties. Dexamethasone can be administered systemically or perineurally and has shown efficacy in enhancing peripheral nerve blocks [10]. Dexamethasone is a long-acting glucocorticoid (half-life >36 hours) with potent anti-inflammatory and analgesic effects [11]. It prolongs nerve block duration by inhibiting nociceptive C-fiber transmission and modulating potassium channel activity in excitable cells [12]. Additionally, dexamethasone induces vasoconstriction, slowing local anesthetic absorption and extending its effect [13]. A single 8 mg dose of intravenous dexamethasone combined with bupivacaine in supraclavicular brachial plexus block has been shown to reduce postoperative pain intensity and prolong analgesia without adverse effects. Its low cost, antiemetic properties, and favorable safety profile make it a practical alternative to perineural administration, especially in resource-limited settings [14]. To date, no studies have investigated this approach in Eritrea, and research on this topic remains scarce. Therefore, this study was conducted to compare the duration of analgesia between two groups—one receiving bupivacaine alone and the other receiving bupivacaine with intravenous dexamethasone—in supraclavicular brachial plexus blocks. We hypothesized that intravenous dexamethasone, when combined with bupivacaine in supraclavicular brachial plexus block, would prolong postoperative analgesia, accelerate the onset of sensory and motor block, and reduce analgesic consumption compared to bupivacaine alone. This hypothesis is based on prior evidence of corticosteroids’ analgesic and anti‑inflammatory properties, as well as their ability to modulate nociceptive transmission and prolong block duration. Materials and methods Study design and setting This study was a hospital-based, randomized clinical trial designed to evaluate the effect of intravenous dexamethasone combined with bupivacaine on prolonging postoperative analgesia following supraclavicular brachial plexus block (SCBPB). It was conducted in the orthopedic department of Halibet National Referral Hospital (HNRH), the sole government-run tertiary center providing orthopedic services in Eritrea. The hospital is located in Asmara, the capital city. Study participants Sixty adult patients scheduled for elective upper limb surgeries under SCBPB were enrolled. Inclusion criteria were: age between 18 and 80 years, ASA physical status I or II, and procedures involving the elbow, forearm, or hand. Exclusion criteria included: patient refusal, contraindications to SCBPB (e.g., severe chronic obstructive pulmonary disease, contralateral diaphragmatic paralysis, neuropathy of the surgical limb), pregnancy, bleeding disorders, local infection at the injection site, known allergy to local anesthetics, long-term steroid therapy, use of premedications that could affect outcomes (opioids, ketamine, NSAIDs), diabetes mellitus, and hepatic or renal disease. Sample size Sample size was calculated to detect differences in the primary outcome (duration of analgesia, measured in hours). Variance estimates were derived from Pawan P.B, (2019), which reported mean durations of 7.5 ± 1.0 hours in controls and 17.3 ± 3.7 hours with dexamethasone. Using α = 0.05 and power = 90%, the minimum required sample size was 7 per group. To improve precision, external validity, and account for potential attrition, we enrolled 30 participants per group. A sensitivity analysis was performed using variance estimates ±20% of those reported in the reference study. These calculations confirmed that a sample size of 30 per group remained sufficient to detect the observed effect. Research variables Primary Outcome: Duration of postoperative analgesia, was defined as the time from block completion to the first request for rescue analgesia or Numeric Rating Scale (NRS) ≥ 4. Analgesic administration thresholds were standardized across participants. Secondary Outcome: Onset of sensory and motor block, Postoperative pain scores, Analgesic consumption Independent variables: Perineural Bupivacaine, intravenous dexamethasone injection, intravenous normal saline Patient variables: Socio-demographic & clinical characteristics. Data collection and anesthesia protocol Sociodemographic and clinical data (age, sex, education, religion, ethnicity, weight, height, ASA status, BMI, prior anesthesia/surgery history, analgesic doses and timing) were collected using a structured checklist. A standard pre-anesthetic assessment was performed, and informed consent obtained. The data collection started on September 23, 2024 and ended on January 17, 2025. All SCBPBs were performed by anesthetists with at least two years of experience in ultrasound-guided techniques. A designated anesthetist administered the block independently. The patients were placed in a supine position. Secure and functional intravenous line was opened. Vital signs were monitored for blood pressure, pulse, and SpO2 and were placed in the arms as required. The site of SCBPB was identified before the drug was administered. A thorough asceptic techniques was used during the block. The brachial nerve plexus was identified using ultrasound by applying an in-plane technique. After drug administration, vital signs were recorded, and sensory/motor block onset was assessed every 2 minutes for 15 minutes. Sensory block assessed via pinprick on a 3-point scale (2 = normal sensation, 1 = loss of pinprick sensation, 0 = loss of light touch). Motor block assessed using the modified Bromage scale (2 = complete block, 1 = reduced strength, 0 = normal function). Vital signs were monitored every 10 minutes until the end of surgery. No single patient in the study group was given sedation. Postoperative pain intensity, time to first analgesic request, type and total analgesic use within 24 hours were recorded. Patients were instructed to self-report pain using the Numeric Rating Scale (NRS), a 10 cm line where 0 = no pain and 10 = worst imaginable pain. Pain scores were recorded at 1, 2, 4, 6, 8, 12, and 24 hours postoperatively. Adverse events (nausea, vomiting, seizures, hypotension, bradycardia, respiratory depression, allergic reactions) were documented. There were no any adverse events throughout the study, details explained in table form in the result section below. Data completeness and consistency were verified. Randomization and blinding Participants were randomized after eligibility confirmation and consent, immediately prior to block administration. The random sequence was generated using a simple lottery method. Sealed opaque envelopes containing group assignments were prepared by an independent staff member not involved in patient care. Allocation concealment was ensured until the envelope was opened at the time of intervention. Block randomization or stratification was not used. Intervention Ethical approval was obtained from the Orotta College of Medicine and Health Sciences Ethics Committee and the Ministry of Health’s Department of Research and Human Resources. The study adhered to CONSORT guidelines. Additional permission was granted by the hospital administration. Participants were randomly assigned to two groups using a simple lottery method. Experimental group received 20 ml of 0.5% bupivacaine plus 8 mg IV dexamethasone and Control group received 20 ml of 0.5% bupivacaine with 2 ml of normal saline. Postoperative monitoring and pain assessments were conducted in the ward at seven time points (1st, 2nd, 4th, 6th, 8th, 12th, and 24th hours). NRS scores and checklist data were used to evaluate pain. Patients requiring additional analgesia or experiencing complications were managed accordingly. Trial registration The trial was registered retrospectively in the Pan African Clinical Trial Registry (PACTR202509579633417). Retrospective registration occurred due to administrative delays and a shortage of stable internet services, which made it difficult to access the registry platform and we acknowledge the risk of reporting bias. Ethical approval was obtained prior to recruitment, and the study protocol was followed throughout. We acknowledge retrospective registration as a limitation. Data analysis data were entered into SPSS version 26.0 (IBM Corp., Chicago, USA). After cleaning, descriptive and inferential statistics were performed. Continuous variables (e.g., duration of analgesia, onset times) were compared using independent samples t‑tests when normally distributed. Mann–Whitney U tests and Shapiro-Wilk and Levene’s test were performed to confirm normality and homogeneity of variance prior to parametric analysis. Categorical variables (e.g., analgesic use, adverse events) were compared using chi‑square or Fisher’s exact tests. Pain scores across time points were analysed using repeated‑measures ANOVA to account for multiple comparisons. Regression analyses adjusting for baseline imbalances (BMI, religion, ethnicity) were performed, with effect sizes and 95% confidence intervals reported. Generalizability This study supports the use of dexamethasone as an adjuvant in low-resource settings, offering prolonged analgesia and reduced burden on healthcare systems. Trial status Recruitment and data collection are complete. Results Sixty patients were assessed for eligibility between September 2024 and January 2025. All 60 met inclusion criteria and were randomized into two groups (30 per group). No patients were lost to follow-up, and no outcome data were missing. The flow of participants through each stage of the trial is shown in Fig 1. CONSORT Flowchart of the participants. Flow diagram of the progress through the phases of a randomised trial of two groups (that is, enrolment, intervention allocation, follow-up, and data analysis). Citation: Hopewell S, Chan AW, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 Statement: updated guideline for reporting randomised trials. BMJ. 2025; 388:e081123. https://dx.doi.org/10.1136/bmj-2024-081123. © 2025 Hopewell et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Baseline characteristics of the patients The baseline demographic and clinical characteristics of the patients are summarized in Table 1. A total of 60 patients were enrolled, with 30 in each group. The median age was comparable between groups (p = 0.317). Female participants comprised 26.7% in both groups. All patients were ASA I, and only one patient in the experimental group had a previous history of anesthesia. 10.1371/journal.pone.0338067.t001Table 1Baseline characteristics of the patients.VariableControl (n = 30)Experimental (n = 30)P valueAge (years, mean ±SD)31.3 ± 2230.3 ± 270.317Sex, n (%)Male: 22 (73.3%)Female: 8 (26.7%)Male: 22 (73.3%)Female: 8 (26.7%)1.000BMI (kg/m2, mean ± SD)20.21 ± 2.1419.21 ± 1.470.039ASA status, n (%)ASA I: 30 (100%)ASA I: 30 (100%)–Previous Anesthesia, n (%)Yes: 0 (0%)No: 30 (100%)Yes: 1 (3.3%)No: 29 (96.7%)1.000Heart rate (beats/min, mean ± SD)78.6 ± 10.481.8 ± 8.90.204Systolic BP (mmHg, mean ± SD)118.2 ± 8.6118.8 ± 8.10.782Diastolic BP (mmHg, mean ± SD)74.1 ± 8.376.5 ± 7.40.228Respiratory rate (breaths/min, mean ± SD)14.1 ± 1.914.0 ± 1.50.817SpO2 (% mean ± SD)98.7 ± 1.198.6 ± 0.90.702Baseline characteristics of patients in the control and experimental groups. Values are presented as mean ± SD or n (%). P values were calculated using independent samples t-test for continuous variables and Fisher’s exact test for categorical variables. ASA = American Society of Anesthesiologists; BMI = Body Mass Index; BP = Blood Pressure; SpO2 = Oxygen saturation. Baseline characteristics of the patients. Baseline characteristics of patients in the control and experimental groups. Values are presented as mean ± SD or n (%). P values were calculated using independent samples t-test for continuous variables and Fisher’s exact test for categorical variables. ASA = American Society of Anesthesiologists; BMI = Body Mass Index; BP = Blood Pressure; SpO2 = Oxygen saturation. BMI was significantly lower in the experimental group compared to the control group (p = 0.039). No significant differences were observed in baseline vital signs, including heart rate, systolic and diastolic blood pressure, respiratory rate, and oxygen saturation (all p > 0.2). These findings confirm that the groups were generally comparable at baseline, except for BMI. Intraoperative vital signs Intraoperative monitoring showed no significant differences in heart rate, systolic or diastolic blood pressure, or respiratory rate between groups at any recorded time point. Oxygen saturation was slightly higher in the control group at 15 minutes (p = 0.021). These trends are illustrated in Fig 2. Intraoperative vital signs in control and experimental groups. Mean values (± SD) for heart rate (A), systolic blood pressure (B), diastolic blood pressure (C), respiratory rate (D), and SpO2 (E) are plotted at 5, 15, 25, 35, 45, and 55 minutes intraoperatively. No significant differences were observed between groups except for SpO2 at 15 minutes (p = 0.021). Regression analyses adjusting for baseline imbalances in BMI, religion, and ethnicity are presented in S1 Table. These analyses confirmed that the observed differences in analgesia duration remained significant after adjustment (β = 9.62 hours, 95% CI 8.41–10.83, p < 0.001). None of the covariates materially altered the primary outcome. Block characteristics and analgesia duration The duration of surgery was similar between groups. However, the duration of analgesia was significantly longer in the experimental group compared to the control group (p < 0.001). The onset of sensory and motor block was also faster in the experimental group. These findings are summarized in Table 2. 10.1371/journal.pone.0338067.t002Table 2Block characteristics and analgesia duration.VariableControlExperimentalP - valueMean ± SDMean ± SDDuration of surgery, in minutes64.60 ± 14.1067.33 ± 16.750.497Duration of analgesia, in hours7.57 ± 1.0417.36 ± 3.75 <0.001 Onset of sensory block, in minutes12.03 ± 2.396.53 ± 1.04 <0.001 Onset of motor block, in minutes15.37 ± 1.969.63 ± 1.38 <0.001 Values are presented as mean ± SD. P values were calculated using independent samples t-test for continuous variables. SD: Standard Deviation. Block characteristics and analgesia duration. Values are presented as mean ± SD. P values were calculated using independent samples t-test for continuous variables. SD: Standard Deviation. Postoperative pain scores Postoperative pain intensity was assessed using the Numeric Rating Scale (NRS) at seven time points. No differences were observed at 1 and 2 hours. However, pain scores were significantly lower in the experimental group at 4, 6, 8, and 12 hours (all p < 0.001). At 24 hours, pain scores remained lower in the experimental group, though not statistically tested due to widespread rescue analgesia. These trends are illustrated in Fig 3. Postoperative pain scores in control and experimental groups. Mean NRS pain scores (± SD) are plotted at 1, 2, 4, 6, 8, 12, and 24 hours postoperatively. The experimental group (bupivacaine + IV dexamethasone) consistently demonstrated lower pain scores compared to the control group (bupivacaine alone), with statistically significant differences at 4, 6, 8, and 12 hours (p < 0.001). At 24 hours, pain scores were descriptively lower in the experimental group, but statistical comparison was not performed due to widespread rescue analgesia. Analgesic consumption Diclofenac use was significantly higher in the control group compared to the experimental group (p < 0.001). Ibuprofen use was not significantly different between groups, while paracetamol use was equal in both groups. These findings are summarized in Table 3. 10.1371/journal.pone.0338067.t003Table 3Analgesic consumption in the control and experimental groups.AnalgesicControl (n = 30)Experimental (n = 30)P valueDiclofenac, n (%)30 (100%)14 (46.7%)≤ 0.001Ibuprofen, n (%)7 (23.3%)3 (10.0%)0.299Paracetamol, n (%)10 (33.3%)10 (33.3%)1.000Values are presented as n (%). P values calculated using Fisher’s exact test. Analgesic consumption in the control and experimental groups. Values are presented as n (%). P values calculated using Fisher’s exact test. Post‑hoc power analysis indicated >80% power for detecting differences in onset times and analgesic consumption, supporting the robustness of these findings. Secondary outcomes were exploratory and interpreted with caution. Adverse events No adverse events were observed in either group. Monitored complications included nausea, vomiting, hypotension, bradycardia, respiratory depression, allergic reactions, and seizures. These findings are summarized in Table 4. 10.1371/journal.pone.0338067.t004Table 4Adverse events in the control and experimental groups.Adverse EventsControl (n = 30)Experimental (n = 30)Nausea00Vomiting00Hypotension00Bradycardia00Allergic Reactions00Respiratory depression00Seizures00Values are presented as n (%). No adverse events were observed in either group during the perioperative period. Adverse events in the control and experimental groups. Values are presented as n (%). No adverse events were observed in either group during the perioperative period. Discussion This randomized clinical trial demonstrated that the addition of 8 mg intravenous dexamethasone to 0.5% bupivacaine in supraclavicular brachial plexus block significantly prolonged postoperative analgesia, accelerated the onset of sensory and motor block, and reduced postoperative analgesic consumption compared with bupivacaine alone. Pain scores were consistently lower in the dexamethasone group at 4, 6, 8, and 12 hours, supporting our hypothesis that systemic corticosteroid administration enhances block quality and duration. Our findings are consistent with earlier reports showing that dexamethasone prolongs the duration of peripheral nerve blocks [8,10,14]. Pawan et al. [15] reported mean analgesia durations of 17.3 hours with dexamethasone compared to 7.5 hours in controls, closely mirroring our results. Other studies have highlighted both perineural and intravenous routes as effective, though the perineural route has raised concerns about neurotoxicity [16]. The intravenous route, as used here, offers a safer and more practical alternative, particularly in resource limited settings where ultrasound guidance and sterile catheter techniques may not be consistently available. Our results therefore add to the growing evidence that intravenous dexamethasone is a viable adjunct for prolonging brachial plexus block analgesia. The magnitude of effect observed in this study was substantial, with a mean difference of nearly 10 hours in analgesia duration between groups. Faster onset of sensory and motor block in the dexamethasone group may be explained by its anti-inflammatory properties and modulation of nociceptive transmission [11–13,17,18]. The reduction in diclofenac use further supports the clinical relevance of this intervention, as decreased reliance on rescue analgesics can improve patient comfort and reduce side effects. Importantly, no adverse events were reported, reinforcing the safety profile of intravenous dexamethasone [19,20]. However, the absence of complications should be interpreted cautiously given the modest sample size [21,22]. Finally, we acknowledge that all enrolled patients were ASA I, representing a healthy, low‑risk cohort. While this enhances internal validity by reducing confounding from comorbidities, it limits generalizability to broader perioperative populations, including diabetic, immunocompromised, or higher‑risk patients in whom dexamethasone’s risk–benefit profile may differ. Future studies should therefore include patients with diverse ASA classifications to better assess external validity. Strengths and limitations Strengths of this study include its randomized design, standardized anesthesia protocol, and comprehensive pain assessment at multiple postoperative time points. The operational definition of analgesia duration was clear and consistent, and outcome assessors were trained anesthetists, reducing measurement bias. Figures were used to present vital signs and pain scores, minimizing redundancy and improving clarity. Several limitations must be acknowledged. First, the trial was registered retrospectively, which may raise concerns about protocol transparency and risk of reporting bias. Second, although randomization was performed using sealed envelopes, baseline imbalances in BMI, religion, and ethnicity were observed; regression analysis was used to adjust for these differences. Third, blinding was partial, as anesthetists administering the block were aware of group allocation and although ward nurses recording NRS scores were not aware of group allocation, they were aware that patients were enrolled in a clinical study. This partial blinding may have introduced expectation bias, as awareness of participation can influence observer diligence and patient reporting. Future studies should ensure full blinding of outcome assessors to minimize this risk. Fourth, although the sample size calculation was based on prior variance estimates, sensitivity analyses confirmed its adequacy, and post‑hoc power commentary supports the robustness of secondary findings. Nonetheless, secondary outcomes remain exploratory and should be interpreted cautiously. Fifth, the study was conducted at a single center with a relatively small sample size, limiting generalizability. Finally, pain scores at 24 hours were not statistically analyzed due to widespread rescue analgesia use, which may have introduced bias. We therefore analyzed pain scores at standardized intervals using repeated‑measures ANOVA and t‑tests, which allowed consistent comparison. Future studies with larger sample sizes and longer follow‑up could incorporate Kaplan–Meier survival analysis to strengthen external validity. Despite these limitations, the results suggest that intravenous dexamethasone is a safe, effective, and practical adjunct to bupivacaine in supraclavicular brachial plexus block [23,24]. Its low cost, ease of administration, and favorable safety profile make it particularly attractive in low resource settings such as Eritrea. Larger multicenter trials are warranted to confirm these findings, explore optimal dosing, and assess long term outcomes. Future research should also investigate patient reported quality of recovery and functional outcomes, which were beyond the scope of this study. Conclusion In summary, intravenous dexamethasone significantly prolonged postoperative analgesia, accelerated block onset, and reduced analgesic consumption without adverse events. These findings support its use as a practical adjunct to bupivacaine in supraclavicular brachial plexus block, with potential to improve postoperative pain management in resource limited environments. Supporting information Supplementary table providing extended data analyses and additional results supporting the main findings of the trial. (DOCX) Complete study protocol document outlining methodology, inclusion/exclusion criteria, anesthesia procedures, and ethical approvals. (DOCX) CONSORT 2025 checklist confirming adherence to randomized clinical trial reporting standards. (DOCX) 22 Jan 2026 Dear Dr. Mengistu, Please submit your revised manuscript by Mar 08 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Robert Jeenchen Chen, MD, MPH, ChFC®, EA Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that you have selected “Clinical Trial” as your article type. PLOS ONE requires that all clinical trials are registered in an appropriate registry (the WHO list of approved registries is at https://www.who.int/clinical-trials-registry-platform/network/primary-registries" https://www.who.int/clinical-trials-registry-platform/network/primary-registries and more information on trial registration is at http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/). Please state the name of the registry and the registration number (e.g. ISRCTN or ClinicalTrials.gov) in the submission data and on the title page of your manuscript. a) Please provide the complete date range for participant recruitment and follow-up in the methods section of your manuscript. b) If you have not yet registered your trial in an appropriate registry, we now require you to do so and will need confirmation of the trial registry number before we can pass your paper to the next stage of review. Please include in the Methods section of your paper your reasons for not registering this study before enrolment of participants started. Please confirm that all related trials are registered by stating: “The authors confirm that all ongoing and related trials for this drug/intervention are registered.” Please see http://journals.plos.org/plosone/s/submission-guidelines#loc-clinical-trials for our policies on clinical trials. 3. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 4. In the online submission form, you indicated that [The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request]. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 6. Please upload a copy of Figure 1, to which you refer in your text on pages 7 and 11. If the figure is no longer to be included as part of the submission please remove all reference to it within the text. 7. We note that you have included two Figure 1’s in your manuscript. Please clarify the captions of these figures accordingly to match the citations that were provided in your manuscript. 8. Figure 2 is not cited in the text. Please review and ensure the Figure is properly cited where necessary. 9. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Tables 3, 4, 5, and 6 in your text; if accepted, production will need this reference to link the reader to the tables. 10. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Partly Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: No Reviewer #3: No ********** Reviewer #1: As the statistical reviewer I will focus on methods and reporting. Major 1) The power calculations need to be presented after the primary outcome has been defined. Then about the power calculations: what was the previous study on which the power calculation was based? it is not referenced. It is unusual for just high variation in the two groups, was that other study large enough? what is mu1 and mu2 in this case? minutes? days? hours? The assumption is for a massive effect, which is problematic when it comes to an RCT 2) the authors are effectively conducting a non-inferiority trial (not a comparison with placebo) without having approached the design as such. This is a major limitation that needs to be clearly discussed since nothing else can be done about it at this late stage. 3) I was not impressed by the structure and quality of writing - reminded me a lot of AI output with bullet points, repetition and very short paragraphs, although that I cannot prove. 4) how did the authors deal with missing data? this needs to be clearly stated in the paper - were all data complete? if yest please state so. 5) there is great variation in characteristics, sand I wouldn't expect that to be the case when randomised properly - the chances of such imbalances are pretty small. that is pretty worrying and also means that regression models need to be used to account for the imbalances, which may be problematic with such a small sample size. 6) linked to 5, move to a regression analysis framework so effect sizes and confidence intervals can be reported, not just p-values. normally, i'd expect a simple regresison with no coavariates except the intervention, but here there exist large imbalances. 7) The trial was registered after completion, which is a major transparency issue Minor 1) "Outcome assessors were blinded". who were these? the statistical analyst? Reviewer #2: General Comment This randomized clinical trial evaluates the effect of intravenous dexamethasone as an adjunct to bupivacaine in supraclavicular brachial plexus block for upper-limb surgery. The topic is clinically relevant, particularly in low-resource settings, and the study reports large and consistent effects on analgesia duration and block characteristics. However, several methodological, reporting, and compliance issues must be addressed to ensure transparency, reproducibility, and adherence to PLOS ONE standards. Major Comments 1. Trial Registration The trial was registered retrospectively in the Pan African Clinical Trial Registry (PACTR202509579633417), after participant recruitment and data collection were completed. • Explicitly justify the reason for retrospective registration. 2. Randomization and Baseline Imbalance Despite randomization, statistically significant baseline differences were observed between groups in: • Religion (p < 0.001) • Ethnicity (p = 0.004) • BMI (p = 0.039) These imbalances raise concerns regarding the effectiveness of the randomization process and may confound outcomes, particularly BMI, which can affect pharmacokinetics and pain perception. 3. Sample Size Calculation and Power The sample size calculation indicates a minimum of 7 participants per group, yet 30 participants per group were enrolled without a clear justification. • Provide a clear rationale for enrolling 30 participants per group (e.g., anticipated attrition, external validity, precision of estimates). • Specify whether the study was powered for secondary outcomes (onset times, pain scores, analgesic consumption). 4. Blinding and Risk of Bias The anesthetist performing the block was not blinded, while participants and outcome assessors were blinded. • Discuss the potential impact of partial blinding in the Limitations section. • Clarify whether IV dexamethasone and normal saline were prepared and administered in an identical manner by an independent staff member. 5. Statistical Analysis and Multiple Comparisons Pain scores were compared at multiple postoperative time points without adjustment for multiple testing. In addition, 24-hour pain scores were reported descriptively but not statistically analyzed. Repeated unadjusted comparisons increase the risk of Type I error. • Justify the absence of correction for multiple comparisons or apply an appropriate method (e.g., repeated-measures analysis). • Clarify why 24-hour pain scores were not statistically compared (e.g., widespread rescue analgesia). 6. Definition of Primary Outcome “Duration of postoperative analgesia” is not operationally defined. • Explicitly define duration of analgesia (e.g., time from block completion to first request for rescue analgesia or NRS ≥4). • State whether analgesic administration thresholds were standardized. Minor Comments 7. CONSORT Reporting Although CONSORT adherence is stated, key methodological details (sequence generation, allocation concealment) require clearer description. • Expand the randomization subsection to explicitly describe sequence generation and envelope handling. • Ensure the CONSORT flow diagram is clearly referenced and consistent with the text. 8. Adverse Events Reporting No adverse events were reported, but this is presented narratively without structured data. • Add a table summarizing monitored adverse events 9. Language and Editorial Issues Several grammatical and stylistic errors are present throughout the manuscript. • Perform thorough language editing to improve clarity and readability. Overall Recommendation Major Revision The manuscript addresses an important clinical issue and shows promising results, but methodological clarification, improved statistical reporting, and compliance with PLOS ONE policies are required before it can be considered for publication. Reviewer #3: ________________________________________ In this study, authors investigated the effect of intravenous dexamethasone combined with bupivacaine on prolonging postoperative analgesia following supraclavicular brachial plexus block. They reported that the addition of 8 mg intravenous dexamethasone to 0.5% bupivacaine in supraclavicular brachial plexus blocks significantly prolonged postoperative analgesia, accelerated the onset of sensory and motor block, and reduced analgesic consumption. The following major revisions are necessary for this study: -What is the authors' hypothesis? On what basis did they conclude that intravenous dexamethasone might improve the success of the block? The hypothesis should be written at the end of the introduction, and the argument should be written based on that hypothesis. - The randomization process should be described in detail, specifying at what stage the patients were randomized. Clarify how the random sequence was generated.Specify who prepared the sealed opaque envelopes and how allocation concealment was ensured. Explicitly state whether block randomization or stratification was considered. -The trial was registered retrospectively, which is a major limitation for a randomized clinical trial. The authors should: provide a clear justification for retrospective registration. Explicitly acknowledge retrospective registration as a limitation. -There's a problem with calculating the sample size. Getting 7 is unlikely. It needs to be recalculated. The sample size calculation suggests that only 7 participants per group were required, yet 30 were included in each group. While over-recruitment can be acceptable, the rationale for this decision is not adequately justified. Additionally: The reported means (μ₁ and μ₂) appear unusually large and their units are unclear. The reference study used for variance estimation should be clearly cited and explained. -Outcome Definitions and Measurement Consistency: The definition of “duration of analgesia” should be clarified (e.g., time from block completion to first request for rescue analgesia). Pain at 24 hours is reported descriptively but not statistically compared; the rationale for this omission should be explained. The use of NRS is appropriate, but the manuscript alternates between NRS and VAS terminology, which should be standardized. -Standard statistical analysis statements should not be written; it should be clearly stated which parameter was compared with which test. -Many grammatical errors and awkward phrasings are present (e.g., “the effective of dexamethasone” instead of “the effect of dexamethasone”). Professional language editing is strongly recommended. -Clarify abbreviations at first mention and avoid redundancy. -Figures should include clear legends and units. Figure numbering appears inconsistent (e.g., Figure 1 vs. Figure 2 in the text). Consort flow diagram?? -It is unnecessary to present the same data in both figures and tables. - Parameters like ‘Educational level, Religious affiliation, Ethnicity’ are unnecessary as they do not affect the study results. The total column in Tables 1 and 2 is also unnecessary. Data can be presented in a single row; simply stating male/female or the number of individuals with an anesthesia history would suffice. The tables should be reorganized, and Tables 1 and 2 should be merged. -Table 3's RR and spo2 are unnecessary. Changes in blood pressure should be presented graphwise; a table is not needed. Table 6 should be rearranged, and Table 5 and Figure 3 should be shown only as figures, with data written below the figure. Figure 1? -The discussion section should include figures and mean-standard deviations. The discussion should be a section interpreting the results. The discussion should be revised to include the results of studies in the literature and the factors influencing the differences in results. The new contribution of this study to the literature should be stated. -The discussion occasionally overstates causality given the study limitations. Comparisons with existing literature are appropriate but could be more concise. The novelty of intravenous (rather than perineural) dexamethasone in this specific setting should be more clearly emphasized. In conclusion, major revisions are necessary. Sincerely yours… ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. Submitted filename: Reviewer comments.docx 2 Feb 2026 Please see the attached detailed response‑to‑reviewers letter. We have carefully addressed each reviewer and editor comment point‑by‑point, with corresponding revisions incorporated into the tracked‑changes and clean versions of the manuscript. Figures and tables have been updated, captions standardized, and all methodological clarifications added as requested. We believe the revised submission fully addresses the concerns raised and strengthens the manuscript. Submitted filename: Response to reviewers.docx 25 Mar 2026 Dear Dr. Mengistu, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 09 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Robert Jeenchen Chen, MD, MPH, ChFC®, EA Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: (No Response) Reviewer #4: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Partly Reviewer #4: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: No Reviewer #4: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #4: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #4: Yes ********** Reviewer #1: I am still not comfortable with this work and I don't need to see it again. I expected my original comments unaltered and the response underneath followed by the resulting changes to the paper, but that was not the case. my original concerns remain in the large. Reviewer #4: - in the intervention section, I would make sure that the intervention in the abstract & methods section agree (ie. potentially including that IV saline was given to the control group) - discussion: instead of "confirming our hypothesis that systemic corticosteroid administration enhances block quality and duration," I suggest a verb more similar to "supporting" - potentially creating a separate subsection for strengths/limitations ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 1 Apr 2026 We recognize Reviewer #1’s continued reservations. While the completed trial design cannot be altered, we have strengthened our statistical analysis by clarifying the primary outcome definition, adjusting for baseline imbalances through regression analyses, and framing conclusions more cautiously. We hope these revisions demonstrate our diligence and transparency. Reviewer #4: We have revised the Abstract and Methods to explicitly state that the control group received intravenous saline, ensuring consistency across sections. In the Discussion, we replaced “confirming our hypothesis” with “supporting our hypothesis” to reflect a more cautious interpretation. Finally, we created a dedicated subsection titled “Strengths and Limitations,” highlighting methodological rigor and acknowledging study constraints such as retrospective registration, partial blinding, and baseline imbalances. Submitted filename: Response_to_reviewers_auresp_2.docx 10 Jun 2026 Dear Dr. Mengistu, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Revise. Please submit your revised manuscript by Jul 25 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Robert Jeenchen Chen, MD, MPH, ChFC®, EA Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: (No Response) Reviewer #5: (No Response) Reviewer #6: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Partly Reviewer #5: Yes Reviewer #6: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: No Reviewer #5: Yes Reviewer #6: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #5: (No Response) Reviewer #6: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: (No Response) Reviewer #5: Yes Reviewer #6: Yes ********** Reviewer #1: nothing further to add............................................................................... Reviewer #5: Thank you for your work on the interesting paper about the impact of dexamethasone on pain management. Dexamethasone, being a corticosteroid does reduce inflammation, which is correlated with pain. This is indicated from the analgesics table. Your results supports that further. Reviewer #6: The authors present a randomized clinical trial evaluating the effect of a single 8 mg intravenous dose of dexamethasone as an adjunct to bupivacaine in supraclavicular brachial plexus block (SCBPB) for upper limb surgery. The topic is clinically relevant, particularly in resource-constrained settings where alternative analgesic strategies—such as continuous perineural catheters or neuraxial opioids—carry practical limitations. The investigators are to be commended for undertaking this work in a setting where such data have historically been sparse. That said, there remain methodological issues that I believe warrant consideration before the manuscript advances. Strengths The most significant strength of this work is its clinical context. Conducting a prospective randomized trial at a single tertiary referral hospital in Eritrea fills a genuine gap in the regional literature, and the authors are transparent about this contribution. The primary outcome—duration of postoperative analgesia, defined clearly as time from block completion to first rescue analgesia request or NRS ≥ 4—is appropriate and operationalized consistently across both arms. The analgesia duration results (17.36 ± 3.75 hours in the dexamethasone group versus 7.57 ± 1.04 hours in controls, p < 0.001) are large in magnitude and closely replicate estimates from prior work cited by the authors (Pawan et al., 2019; Saba et al., 2020), lending face validity to the findings. The revised manuscript also benefits from the addition of a dedicated Strengths and Limitations subsection, improved consistency in reporting the control group's IV saline administration, and the more measured language in the Discussion ("supporting" rather than "confirming" the hypothesis). These changes reflect a genuine responsiveness to reviewer feedback. The CONSORT flow diagram and the structured adverse events table are appropriate additions. Statistical Appropriateness The choice of independent-samples t-tests for the primary outcome is reasonable given the sample sizes and the apparent normality assumptions, though the manuscript would benefit from explicitly reporting whether Shapiro-Wilk or Levene's tests were performed prior to parametric analyses, particularly given the asymmetric SDs (e.g., the experimental group's analgesia duration SD of 3.75 hours vs. 1.04 in controls is notably skewed). The use of repeated-measures ANOVA for postoperative NRS scores is appropriate and addresses the prior reviewer concern about multiple comparisons. The sample size calculation deserves more scrutiny than it has received across revision cycles. A minimum of 7 subjects per group to detect the primary effect is correct arithmetically, but the variance estimates were drawn directly from the very study (Pawan et al.) whose results the authors then nearly exactly replicate—this circularity inflates the apparent adequacy of 30 per group and should be discussed more explicitly as a limitation. Relatedly, the authors justify enrolling 30 per group on grounds of "precision, external validity, and attrition," but these rationale lack quantitative grounding. A brief sensitivity analysis or commentary on the trial's post-hoc power for secondary outcomes would strengthen this section considerably. The regression analyses performed to adjust for baseline imbalances in BMI, religion, and ethnicity are a welcome addition. However, the manuscript does not report the actual regression coefficients, adjusted effect estimates, or confidence intervals in any table—it only references that regression was performed. These results should be presented explicitly, even in a supplementary table, to allow the reader to assess whether the observed imbalances materially affect the primary conclusions. Limitations and Weaknesses Several limitations are acknowledged by the authors but deserve amplification. First, the retrospective trial registration (PACTR202509579633417) remains a substantive concern that cannot be fully mitigated by explanation alone. Retrospective registration introduces the possibility of outcome reporting bias that prospective registration is designed to prevent. The explanation offered—administrative delays and internet access difficulties—is contextually plausible given the study setting, but the reader should weigh this caveat accordingly. Second, partial blinding is a structural limitation with real implications for this trial. The anesthetists administering the block were aware of group allocation, and though pain scores were recorded by ward nurses using a standardized scale, the manuscript does not clearly describe whether those ward nurses were blinded to treatment assignment. If they were not, NRS scoring could be susceptible to expectation bias, particularly given the subjective nature of pain reporting. This should be stated more explicitly. Third, the 24-hour NRS data are reported descriptively but not analyzed due to widespread rescue analgesia use in the control group—an entirely defensible decision. However, the resulting analytic gap leaves the manuscript unable to characterize the duration of the dexamethasone effect's decay and its convergence with the control group. A time-to-event analysis (e.g., survival analysis for analgesia duration) would have been more informative than a simple t-test of means and would have better handled the censoring inherent in rescue analgesia. Fourth, the reference list contains several entries with incomplete bibliographic data. References 4, 7, 9, 10, 13, 14, 17, 20, 21, 22, 23, and 24 are missing journal names, volume numbers, and page ranges. Reference 12 (Suzuki et al., Local Anesthetics, Pharmacology and Physiology for Anesthesia, Elsevier, 2019) is cited in support of the claim that dexamethasone induces vasoconstriction—a mechanism more appropriately attributed to a primary dexamethasone pharmacology source. These should be corrected and verified for accuracy before publication. Minor Points The trial registration section on the title page contains an apparent typographic error: recruitment is listed as occurring between "September 23, 2025 and January 17, 2025"—a logically impossible date range. This presumably reflects a typo (2024, not 2025) but must be corrected, as it undermines confidence in manuscript proofreading. The contribution statement contains a typo ("ollection" rather than "collection") that was present in the prior submission and has not been corrected in the revised version. The Discussion section would benefit from a more explicit acknowledgment that all enrolled patients were ASA I—a notably low-risk, healthy cohort that may limit generalizability to the broader perioperative population, including diabetic or immunocompromised patients in whom dexamethasone's risk profile is more nuanced. Summary Overall, this manuscript addresses a meaningful clinical question in an underrepresented setting and reports large, internally consistent findings. The revisions undertaken across multiple review cycles have improved the manuscript's transparency and methodological reporting. The remaining concerns—particularly around regression result reporting, blinding of ward nurses, the registration timeline error, and incomplete references—are addressable and should be resolved before acceptance. I would recommend Major Revision. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #5: No Reviewer #6: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 17 Jun 2026 Reviewer #1: We have added explicit reporting of Shapiro–Wilk and Levene’s tests to confirm statistical assumptions, and expanded regression reporting with adjusted effect estimates, confidence intervals, and a supplementary table. Reviewer #5: We appreciate the recognition of the clinical relevance of dexamethasone. The analgesics table has been proofread and clarified for consistency. Reviewer #6: We have incorporated a sensitivity analysis for sample size, added post‑hoc power commentary, clarified retrospective trial registration, and acknowledged partial blinding with potential expectation bias. We also explicitly note that all patients were ASA I, limiting generalizability, and explain why time‑to‑event analysis was not feasible, while recommending survival analysis in future larger studies. References and typographic errors have been corrected. Submitted filename: Response_to_Reviewers_June2026.docx.docx 8 Jul 2026 Dear Dr. Mengistu, Please submit your revised manuscript by Aug 22 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Robert Jeenchen Chen, MD, MPH, ChFC®, EA Academic Editor PLOS One Journal Requirements: 1. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments: Revise [Note: HTML markup is below. Please do not edit.] Reviewer's Responses to Questions Comments to the Author Reviewer #1: (No Response) Reviewer #7: (No Response) Reviewer #8: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: (No Response) Reviewer #7: No Reviewer #8: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: (No Response) Reviewer #7: Yes Reviewer #8: No ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: (No Response) Reviewer #7: No Reviewer #8: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: (No Response) Reviewer #7: Yes Reviewer #8: No ********** Reviewer #1: ......................................................................................................................................................... Reviewer #7: Abstract: - method is incomplete and the inclusion criteria are not exactly clear especially age, ASA class and elective or emergency and also type of operation. -primary and secondary outcomes are not mentioned. - It is better that results write comparatively and the numerical values of intensity and time between the 2 groups should be mentioned. introduction: - It would better to use newer references and the contents should be cited from recent references. Material and Methods: - This item is not complete. - The specification and manufacture company of usage drugs should be mentioned. - The side effects including hypotension, bradycardia and respiratory depression should be defined and the method of managing them should be explained. - The groups maybe not matched according to type of surgery(skeletal or soft tissue) and emergency or elective operation. These items should be mentioned. - The technique of performing procedures must be fully described such as: patient positioning, procedure landmark and type of ultrasound-guided usage. - How has the duration of operation been calculated. At what time and by whom was the onset of speed of the sensory and motor block assessed. - Randomization and blindness should be completely explained. - How was the postoperative pain management? such as: depend on NRS score, type of analgesic drugs and etc - Did the patients receive any sedation during the operation? Have they had any failed block? Please fully explained and the Diagram consort should also be included. Results: - All results are not presented such as : side effects including hypotension. bradycardia, respiratory depression , nausea and vomiting etc - Is there date available regarding analgesic usage by time interval of assessing? If there is, please attach it and provide explanation in the discussion. - The way that results are expressed is not interesting, for example some results can be expressed as figure such as : the hemodynamic parameters Discussion: - The discussion is incomplete and scattered. The findings are not correctly described. - It is advisable to explain and further discuss on the results regarding the pharmacokinetic and pharmacodynamic of dexamethasone such as : the onset and the mechanism of action, duration of action and its therapeutic effect. References: - Most of the references are quiet old and it would better to replace them with more recent ones. Reviewer #8: “The Effect of Intravenous Dexamethasone in Supraclavicular Brachial Plexus Block at Halibet National Referral Hospital, Eritrea 2024 - 2025: A Randomized Clinical Trial” The full title brings confusion in some way. Intravenous dexamethasone with SCBPB may be better. Intravenous dexamethasone has been demonstrated to prolong analgesia similarly to perineural administration, which limits the novelty of this finding. However, this report does provide a comparison of the onset of supraclavicular brachial plexus block (SCBPB) and the sequential analgesic effects following upper limb surgery. Abstract The abstract needs an extensive revision to make it clear. Such as Background: 4th line, This study aimed to evaluate the impact of adding intravenous dexamethasone on postoperative analgesia in conjunction with SCBPB for upper limb surgeries. Methods The 2nd line, Regarding the timing of performing SCBPB with 20 mL of 0.5% bupivacaine, the control group received 2 mL of normal saline intravenously, while the experimental group received the same intravenous volume containing 8 mg of dexamethasone. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #7: No Reviewer #8: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 22 Jul 2026 We believe these revisions address all outstanding concerns from Reviewer #7 and Reviewer #8. The manuscript has been revised and polished to meet the criteria of PLOS ONE. Most of the comments provided by the recent reviewers were already addressed in the previous cycle of revision, and we have highlighted where these clarifications are present. Given the extensive revisions and multiple independent reviews already completed, we respectfully request that the editor consider this version suitable for publication in PLOS ONE. Submitted filename: Response_to_Reviewers_July2026.docx.docx 28 Jul 2026 Dear Dr. Mengistu, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Revise. Please submit your revised manuscript by Sep 11 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Robert Jeenchen Chen, MD, MPH, ChFC®, EA Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: All comments have been addressed Reviewer #7: All comments have been addressed Reviewer #8: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: Yes Reviewer #7: Yes Reviewer #8: Partly ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #7: Yes Reviewer #8: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #7: Yes Reviewer #8: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #7: Yes Reviewer #8: No ********** Reviewer #1: All comments have been addressed. I have nothing else to raise.,..........,,... .......... Reviewer #7: please revised and responded to all recommendation and highlight them in the text. I can not see all revision in the text. Reviewer #8: As a reviewer, my role is to assist authors in clearly presenting their research. Unfortunately, the revised version does not meet this objective. Below are my suggestions: Background: Postoperative pain has a significant impact on recovery and healthcare costs. While effective regional anesthesia provides both anesthesia and analgesia, its effects are often of limited duration. Previous studies indicate that intravenous dexamethasone may enhance and prolong analgesia when used with regional blocks, yet reports on its addition to supraclavicular brachial plexus block (SCBPB) for upper limb surgeries are limited. We hypothesized that intravenous dexamethasone would extend postoperative analgesia following SCBPB. Method: A randomized clinical trial was conducted at Halibet National Referral Hospital in Eritrea, involving 60 patients undergoing upper limb surgery who received SCBPB with 20 ml of 0.5% bupivacaine. Concurrently, the control group received 2 ml of normal saline, while the experimental group received 2 ml (8 mg) of intravenous dexamethasone. Pain scores, time to first rescue analgesia, and analgesic consumption were recorded. Data were analyzed using SPSS v26. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #7: No Reviewer #8: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 3 Aug 2026 We thank all the reviewers for their constructive comments and suggestions. Submitted filename: Response_to_Reviewers_August2026.docx.docx 11 Aug 2026 The Effect of Intravenous Dexamethasone in Supraclavicular Brachial Plexus Block at Halibet National Referral Hospital, Eritrea 2024 - 2025: A Randomized Clinical Trial PONE-D-25-60591R5 Dear Dr. Mengistu, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Robert Jeenchen Chen, MD, MPH, ChFC®, EA Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #1: (No Response) Reviewer #7: All comments have been addressed Reviewer #8: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #1: (No Response) Reviewer #7: Yes Reviewer #8: (No Response) ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: (No Response) Reviewer #7: Yes Reviewer #8: (No Response) ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: (No Response) Reviewer #7: Yes Reviewer #8: (No Response) ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: (No Response) Reviewer #7: Yes Reviewer #8: (No Response) ********** Reviewer #1: .............................................................................................................................. Reviewer #7: Please mention the specification of drugs usage(Bupivacaine and Dexamethasone) including volume of vial, mg per ml, and the company and country of manufacture. Reviewer #8: (No Response) ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #7: No Reviewer #8: No ********** PONE-D-25-60591R5 PLOS One Dear Dr. Mengistu, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Robert Jeenchen Chen Academic Editor PLOS One